Article Sidebar

PDF
Date Published: 19/08/2024
Abstract Views: 107
Views PDF: 69
DOI: https://doi.org/10.51298/vmj.v541i2.10777
Issue
Vol. 541 No. 2 (2024)
Section
Các bài báo
How to Cite
Pham, C., Dương, Q. H., Pham, X. H., Pham, Q. T., & Ngô, T. T. (2024). ASSOCIATION OF TERT C228T PROMOTER MUTATION IN PERIPHERAL BLOOD WITH TNM STAGE IN HEPATITIS B VIRUS - INFECTED HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 541(2). https://doi.org/10.51298/vmj.v541i2.10777

ASSOCIATION OF TERT C228T PROMOTER MUTATION IN PERIPHERAL BLOOD WITH TNM STAGE IN HEPATITIS B VIRUS - INFECTED HEPATOCELLULAR CARCINOMA

Châu Pham, Quang Huy Dương, Xuân Huy Pham, Quang Trung Pham, Tất Trung Ngô

Main Article Content

Abstract

Objective: To evaluate the association between the TERT C228T promoter mutation in peripheral blood and the TNM stage in patients with hepatocellular carcinoma (HCC) infected with Hepatitis B virus (HBV). Subjects and methods: A cross-sectional descriptive study was conducted on 159 newly diagnosed HCC patients with HBV infection at Military Hospital 103 and the 108 Central Military Hospital. The TERT C228T promoter mutation in peripheral blood was identified using gene amplification by Nested-PCR combined with Realtime PCR. Results: The rate of TERT C228T mutation in peripheral blood was 25.2%. The mutation rate was related to tumor stage (38.0% in stage T3, T4 vs. 19.3% in stage T1, T2, p<0.05) and increased gradually with disease stage from 10.3% in stage I to 48.0% in stage IV, p <0.05. Conclusion: The TERT promoter C228T mutation in plasma of HCC patients with HBV infection is related to tumor stage and overall stage of HCC, suggesting that this could be a potential prognostic marker.

Article Details

Keywords

Hepatocellular carcinoma, TERT C228T, HBV infection

References

1. Vauthey J.N., Lauwers G.Y., Esnaola N.F. et al., Simplified staging for hepatocellular carcinoma. J Clin Oncol, 2002. 20(6): 1527-36.
2. Akinyemiju T., Abera S., Ahmed M. et al., The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol, 2017. 3(12): 1683-1691.
3. Robinson N.J., Schiemann W.P., Telomerase in Cancer: Function, Regulation, and Clinical Translation. Cancers (Basel), 2022. 14(3).
4. Nault J.C., Ningarhari M., Rebouissou S. et al., The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol, 2019. 16(9): 544-558.
5. Pezzuto F., Buonaguro L., Buonaguro F.M. et al., Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer, 2017. 12: 27.
6. Marrero J.A., Kulik L.M., Sirlin C.B. et al., Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018. 68(2): 723-750.
7. Amin M.B., Edge S., Greene F. et al., AJCC cancer staging manual. 8th ed. New York:. Springer; 2017. [Google Scholar], 2017.
8. Lê Văn Thu, Hồ Cẩm Tú, Nguyễn Quý Linh và CS. Tỷ lệ đột biến vùng promoter gen TERT trên bệnh nhân ung thư biểu mô tế bào gan. Tạp chí Khoa học công nghệ Việt Nam, 2022. 64(2): 5-9.
9. Yang X., Guo X., Chen Y. et al., Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2016. 7(19): 27838-47.
10. Oversoe S.K., Clement M.S., Pedersen M.H. et al., TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand J Gastroenterol, 2020. 55(12): 1433-1440.